DEF: Celldex Therapeutics Seeks Stockholder Approval for Equity Incentive Plan Amendment

Celldex Therapeutics is asking stockholders to approve an amendment to its 2021 Omnibus Equity Incentive Plan, increasing the number of shares available for issuance by 2,000,000 to a total of 9,500,000, plus any unused shares from the 2008 plan.

Summary

• Celldex Therapeutics is holding its Annual Meeting of Stockholders on June 5, 2025, to vote on several proposals.
• The proposals include electing nine directors, ratifying the appointment of PricewaterhouseCoopers LLP as the independent accounting firm, approving an amendment to the 2021 Omnibus Equity Incentive Plan, and conducting an advisory vote on executive compensation.
• The key proposal involves amending the 2021 Omnibus Equity Incentive Plan to increase the number of shares reserved for issuance by 2,000,000, bringing the total to 9,500,000 plus any unused shares from the 2008 plan.
• The board believes this increase is necessary to attract and retain talent, especially as the company plans for potential commercialization.
• Stockholders of record as of April 9, 2025, are eligible to vote.
• The Board of Directors recommends voting FOR all proposals.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a positive outlook on attracting and retaining talent. The sentiment is neutral to slightly positive.

Positives

• The proposed amendment to the equity incentive plan aims to attract and retain talented personnel, which is crucial for the company's future success.
• The company has a strong cash position of $725 million.
• The company is making progress across the barzolvolimab clinical program, including the initiation of Phase 3 trials.
• The company is progressing its bispecific clinical and preclinical programs.

Risks

• If the stockholders do not approve the amendment to increase the number of shares available for issuance under the Plan, the Company will continue to operate the Plan under its current provisions.
• The life sciences industry is highly competitive, and the company's results are largely attributable to the talents, expertise, efforts and dedication of its employees.

Future Outlook

The company is planning a global Phase 3 program in chronic inducible urticaria (CIndU), which is expected to initiate in 2025.

Management Comments

• Our Board believes that the granting of stock options, restricted stock awards and other kinds of equity-based compensation promotes continuity of management and increases incentive and personal interest in the welfare of our Company and alignment with shareholders by those who are primarily responsible for shaping and carrying out our long-range plans and securing our growth and financial success.

Industry Context

The life sciences industry is highly competitive, and Celldex faces competition for skilled personnel from both large pharmaceutical companies and other development-stage life science companies.

Comparison to Industry Standards

• The Compensation and Organization Development Committee has adopted a compensation philosophy of targeting our executive compensation to the 50 th percentile of executive compensation of our peer group and the Aon Global Life Sciences (Aon) Survey results.
• Executive compensation may be above or below the 50 th percentile based on an executives experience, scope of position, individual performance and company constraints.

Stakeholder Impact

• Approval of the equity incentive plan amendment could positively impact employees by providing them with equity-based compensation.
• Approval of the equity incentive plan amendment could positively impact shareholders by aligning employee interests with long-term company success.

Next Steps

• Stockholders to vote on the proposals at the Annual Meeting on June 5, 2025.
• The company will continue to execute its clinical development programs and prepare for potential commercialization.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, directors, executive compensation, equity incentive plan, PricewaterhouseCoopers, shares, amendment, Celldex Therapeutics